Stock listing

BX Swiss:TEV Teva Pharmaceutical Industries Limited Aktie

Swiss listing (BX Swiss) of Teva Pharmaceutical Industries Limited · home listing TASE:TEVA

Follow Teva Pharmaceutical Industries Limited into a list and get an email when it puts out news.

Home listing price · TASE:TEVA

13,330 ILA (agorot) -590 (-4.2%)

Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TASE:TEVA

Past year +64.4% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
13,260 – 13,780 ILA (agorot)Nov 19, 2026
Volume
1.09M sharesNov 19, 2026
Market cap
155.5B ILSAt the close on Nov 19, 2026 · price × 1.17B shares outstanding
52-week range
7,915.00 – 14,440 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
164.5M ILSMedian day 1.05M shares · 5 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
Teva Pharmaceutical Industries Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TASE:TEVA · Home13,330 ILA (agorot)-590 (-4.2%)1,091,16313,78013,78013,26013,920Close on Nov 19, 2026
NYSE:TEVA$39.23 USD+0.69 (+1.8%)6,809,187$38.46$39.91$38.30$38.54Close on Nov 20, 2026
B3:T1EV34122.30 BRL-1.80 (-1.5%)4122.30122.30122.30124.10Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:TEVA · ILA (agorot), adjusted for splits

DayCloseChange%OpenHighLowVolume
13,330-590-4.2%13,78013,78013,2601,091,163
13,920+240+1.8%13,82014,07013,820822,689
13,680-470-3.3%13,89013,90013,580924,287
14,150+180+1.3%14,30014,44014,1501,641,795
13,970+430+3.2%13,77014,03013,7401,570,791
13,540+50+0.4%13,58013,82013,4501,303,243
13,490-90-0.7%13,58013,60013,4001,143,841
13,580+280+2.1%13,52013,84013,4701,433,958
13,300+120+0.9%13,35013,39013,1601,028,753
13,18000.0%13,13013,34013,02014,956,833
13,180-390-2.9%13,10013,26012,9002,733,286
13,570+490+3.7%12,77013,57012,7002,946,686
13,080+280+2.2%13,04013,12012,3103,585,767
12,800+80+0.6%12,81012,91012,7301,021,023
12,720+110+0.9%12,38012,79012,3801,308,939
12,610+360+2.9%12,32012,66012,2101,519,647
12,250-70-0.6%12,18012,27012,0101,351,741
12,320-90-0.7%12,41012,49012,2501,253,715
12,410-170-1.4%12,52012,60012,3901,152,711
12,580-270-2.1%12,73012,77012,1902,111,248
12,850-80-0.6%12,89013,07012,760978,093
12,930+110+0.9%13,00013,05012,8201,057,342
12,820-110-0.9%12,93012,93012,740507,479
12,930-10-0.1%12,56012,99012,5401,008,583
12,940+200+1.6%12,73012,94012,620971,415
12,740+110+0.9%12,61012,78012,530980,586
12,630+630+5.3%12,61012,73012,5501,611,466
12,000+230+2.0%11,98012,06011,910671,471
11,770-220-1.8%11,88011,99011,7701,291,493
11,990-20-0.2%11,90012,09011,8201,153,909
12,010+10+0.1%12,20012,20012,0001,216,909
12,000-160-1.3%12,12012,15012,000853,894
12,16000.0%12,16012,16012,1600
12,160-150-1.2%12,20012,30012,140892,287
12,310+340+2.8%12,10012,31012,0801,011,870
11,970+130+1.1%12,00012,04011,920879,177
11,840-210-1.7%11,90011,93011,750669,308
12,05000.0%12,05012,05012,0500
12,050-10-0.1%11,76012,06011,7301,570,387
12,060+20+0.2%11,89012,08011,7801,262,779
12,040+80+0.7%12,04012,15011,8701,541,251
11,96000.0%11,96011,96011,9600
11,96000.0%11,96011,96011,9600
11,960+160+1.4%11,78011,96011,6001,562,605
11,800+90+0.8%11,90011,99011,6401,135,971
11,710+170+1.5%11,69011,90011,6601,124,143
11,540+420+3.8%11,19011,60011,180950,706
11,12000.0%11,12011,12011,1200
11,120-10-0.1%11,20011,26011,0301,052,520
11,130+210+1.9%11,07011,25010,9601,048,196
10,920+10+0.1%10,92011,02010,6801,086,826
10,910-50-0.5%10,97011,05010,820499,288
10,960-40-0.4%11,09011,09010,900473,654
11,000-10-0.1%11,31011,45010,970983,311
11,010-10-0.1%10,87011,53010,8201,791,302
11,020+310+2.9%10,82011,03010,7801,141,409
10,710-320-2.9%10,94011,00010,660905,060
11,030-180-1.6%11,02011,14010,9801,399,391
11,210+50+0.4%11,16011,28011,120812,651
11,160-50-0.4%11,25011,44011,010740,192
11,210+120+1.1%11,09011,23011,0501,192,310
11,090+70+0.6%11,18011,22011,040727,266
11,020-80-0.7%11,03011,07010,930285,212
11,100-110-1.0%11,15011,19011,030625,182
11,210+130+1.2%10,95011,24010,850937,718

Splits

2 splits since 2002 · TASE:TEVA · every price before a split is adjusted for it

DayRatioWhat
2-for-1Split
2-for-1Split
Ticker
BX Swiss:TEV
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BX Swiss
Currency
CHF

What changed lately

Latest news

Teva Releases Q3 2026 Aide Memoire

Sep 23, 2026

Closed 12,050 (-0.1%) on Sep 24, 2026

All Teva Pharmaceutical Industries Limited news

Teva Pharmaceutical Industries Limited on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
41 in the last 12 months · 90 in all · newest Oct 1, 2026 · oldest 2025
Calls
32 calls with a replay · 32 with a transcript · latest Nov 3, 2026
Decks
167 decks · latest Nov 3, 2026

Where Teva Pharmaceutical Industries Limited is listed

ListingExchangeCountryCurrency
TASE:TEVA · Home listingTASEIsraelILA
NYSE:TEVANYSEUnited StatesUSD
gettex:TEVgettexGermanyEUR
Frankfurt:TEVFrankfurtGermanyEUR
Tradegate:TEVTradegateGermanyEUR
BOATS:TEVABOATSUnited StatesUSD
OTC:TEVJFOTCUnited StatesUSD
LS Exchange:883035LS ExchangeGermanyEUR
B3:T1EV34B3BrazilBRL
BMV:TEVANBMVMexicoMXN
VIE:TEVAViennaAustriaEUR
BX Swiss:TEV · This pageBX SwissSwitzerlandCHF
LSIN:0LERLSINUnited KingdomUSD
Stuttgart:TEVStuttgartGermanyEUR
Hanover:TEVHanoverGermanyEUR
Lang & Schwarz:883035Lang & SchwarzGermanyEUR
BSESOF:TEVBSESOFBulgariaEUR
Dusseldorf:TEVDusseldorfGermanyEUR
Hamburg:TEVHamburgGermanyEUR
Munich:TEVMunichGermanyEUR

Valuation

P/E 89.8× against a median of 29.7×: 10th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 19, 2026

Enterprise value
155.3B ILS
P/E
89.8×
EV/sales
3.3×
EV/EBITDA
13.5×
Price/book
5.8×
Gross margin
66.1%
Operating margin
17.3%
Net margin
3.7%
Debt to equity
0.5×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Teva Pharmaceutical Industries Limited · TASE:TEVAUS$46.34BUS$46.29B89.8×3.3×13.5×5.8×3.7%0.5×n/a
argenx SE · EURONEXT:ARGXUS$58.86BUS$53.72B22.8×6.5×n/a7.0×31.4%0.0×n/a
Roche Holding Ltd · SIX:ROUS$51.16BUS$77.45B3.3×1.1×2.9×1.3×20.9%1.0×n/a
Sun Pharmaceutical Industries Limited · NSE:SUNPHARMAUS$48.81BUS$45.53B41.2×6.8×24.4×5.1×17.8%0.0×n/a
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A · SSE:600276US$45.00BUS$38.46B33.8×7.8×n/a4.5×27.0%0.0×n/a
Sandoz Group Ltd · SIX:SDZUS$41.49BUS$46.45B43.3×4.2×23.6×4.6×8.6%0.7×n/a
Celltrion, Inc. · KRX:068270US$36.08BUS$35.44B30.8×9.7×25.9×2.7×32.2%0.0×n/a
Zoetis Inc. · NYSE:ZTSUS$32.69BUS$40.21B13.0×4.2×10.2×9.9×26.4%2.7×0.69
Divi's Laboratories Limited · NSE:DIVISLABUS$32.03BUS$32.03B101×26.4×74.8×17.7×26.1%0.0×n/a
Hansoh Pharmaceutical Group Company Limited · HKEX:3692US$23.78BUS$18.80B28.5×8.3×21.6×4.2×37.0%0.1×n/a
United Therapeutics Corporation · NASDAQ:UTHRUS$23.63BUS$21.56B19.2×6.8×15.2×3.8×38.6%0.0×0.46
Median of the othersUS$38.78BUS$39.33B29.7×6.8×22.6×4.5×26.7%0.0×0.57

Forecasts

Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
11.00 ILA · Analysts' mean
Revenue, year to Dec 2026
16.79B · 12 analysts

Team and board

Officers

OfficerRole
Richard FrancisPresident and Chief Executive Officer, Member of the Board of Directors
Edward JordanEVP and head of Commercial Operations North America

Board

DirectorRole
Sol J. BarerChairman of the Board Independent Director
Amir ElsteinIndependent Director
Chen LichtensteinIndependent Director
Gerald M. LiebermanIndependent Director
Perry D. NisenIndependent Director
Richard FrancisPresident and Chief Executive Officer, Member of the Board of Directors
Roberto A. MignoneIndependent Director
Ronit Satchi-FainaroIndependent Director
Rosemary A. CraneIndependent Director
Tal ZaksIndependent Director

Events

Next results
Jan 27, 2027 (expected)

Calls

CallWhenStatus
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2026 Earnings CallTue, Nov 03, 2026 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q2 2026 Earnings CallWed, Jul 29, 2026 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q1 2026 Earnings CallWed, Apr 29, 2026 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q4 2025 Earnings CallWed, Jan 28, 2026 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2025 Earnings CallWed, Nov 05, 2025 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q2 2025 Earnings CallWed, Jul 30, 2025 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q1 2025 Earnings CallWed, May 07, 2025 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q4 2024 Earnings CallWed, Jan 29, 2025 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2024 Earnings CallWed, Nov 06, 2024 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q2 2024 Earnings CallWed, Jul 31, 2024 · 8:00 AM ETReplay
All 32 calls
CallWhenStatus
Teva Pharmaceutical Industries (TASE:TEVA) Q1 2024 Earnings CallWed, May 08, 2024 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q4 2023 Earnings CallWed, Jan 31, 2024 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2023 Earnings CallWed, Nov 08, 2023 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q2 2023 Earnings CallWed, Aug 02, 2023 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q1 2023 Earnings CallWed, May 10, 2023 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q4 2022 Earnings CallWed, Feb 08, 2023 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2022 Earnings CallThu, Nov 03, 2022 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q2 2022 Earnings CallWed, Jul 27, 2022 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q1 2022 Earnings CallTue, May 03, 2022 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q4 2021 Earnings CallWed, Feb 09, 2022 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2021 Earnings CallWed, Oct 27, 2021 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q2 2021 Earnings CallWed, Jul 28, 2021 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q1 2021 Earnings CallWed, Apr 28, 2021 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q4 2020 Earnings CallWed, Feb 10, 2021 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2020 Earnings CallThu, Nov 05, 2020 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q2 2020 Earnings CallWed, Aug 05, 2020 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q1 2020 Earnings CallThu, May 07, 2020 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q4 2019 Earnings CallWed, Feb 12, 2020 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q3 2019 Earnings CallThu, Nov 07, 2019 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q2 2019 Earnings CallWed, Aug 07, 2019 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q1 2019 Earnings CallThu, May 02, 2019 · 8:00 AM ETReplay
Teva Pharmaceutical Industries (TASE:TEVA) Q4 2018 Earnings CallWed, Feb 13, 2019 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 3, 2026 · Before open+3.8%
Q1 2025May 7, 2025 · Before open+0.8%
Q4 2024Jan 29, 2025 · Before open−14.8%
Q3 2024Nov 6, 2024 · Before open−4.3%
Q2 2024Jul 31, 2024 · Before open+4.2%
Q1 2024May 8, 2024 · Before open+13.0%
Q4 2023Jan 31, 2024 · Before open+3.9%
Q3 2023Nov 8, 2023 · Before open−0.3%
Q2 2023Aug 2, 2023 · Before open+13.2%
Q1 2023May 10, 2023 · Before open−8.0%
All 19 quarters
QuarterResultsShare move
Q4 2022Feb 8, 2023 · Before open−3.7%
Q3 2022Nov 3, 2022 · Before open−2.5%
Q2 2022Jul 26, 2022 · After close+21.1%
Q1 2022May 3, 2022 · Before open+1.9%
Q4 2021Feb 9, 2022 · Before open+10.5%
Quarter to Sep 30, 2021Oct 27, 2021 · Before open−6.7%
Quarter to Jun 30, 2021Jul 28, 2021 · Before open+12.0%
Quarter to Mar 31, 2021Apr 28, 2021 · Before open−1.9%
Quarter to Dec 31, 2020Feb 10, 2021 · Before open−9.2%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings70 slidesNov 3, 2026
Corporate Update (October 2026)Corporate update15 slidesOct 9, 2026
IL-15 Celiac Disease Phase 2a Topline Results - Conference Call (September 2026)Conference23 slidesSep 2, 2026
Q2 2026 Earnings PresentationEarnings74 slidesJul 29, 2026
Technical Presentation (July 2026)Technical19 slidesJul 7, 2026
Technical Presentation (July 2026)Technical18 slidesJul 7, 2026
Q1 2026 Earnings PresentationEarnings73 slidesApr 29, 2026
Corporate Update (February 2026)Corporate update25 slidesFeb 17, 2026
Q4 2025 Earnings PresentationEarnings71 slidesJan 28, 2026
44th Annual J.P. Morgan Healthcare Conference 2026Conference20 slidesJan 13, 2026
Show 50 decks
DeckKindSlidesDate
ESG Presentation (December 2025)Sustainability48 slidesDecember 2025
Q3 2025 Earnings PresentationEarnings73 slidesNov 5, 2025
Technical Presentation (September 2025)Technical27 slidesSep 22, 2025
Q2 2025 Earnings PresentationEarnings68 slidesJul 30, 2025
Investor Day (May 2025)Investor day99 slidesMay 29, 2025
Q1 2025 Earnings PresentationEarnings60 slidesMay 7, 2025
ECCO 2025 investor callConference28 slidesFeb 24, 2025
Q4 2024 Earnings PresentationEarnings62 slidesJan 29, 2025
43rd Annual J.P. Morgan Healthcare Conference (January 2025)Conference32 slidesJan 13, 2025
Corporate Update (December 2024)Corporate update24 slidesDec 17, 2024
ESG Presentation (December 2024)Sustainability43 slidesDecember 2024
Q3 2024 Earnings PresentationEarnings56 slidesNov 6, 2024
Q2 2024 Earnings PresentationEarnings57 slidesJul 31, 2024
Q1 2024 Earnings PresentationEarnings57 slidesMay 8, 2024
Q4 2023 Earnings PresentationEarnings56 slidesJan 31, 2024
42nd Annual J.P. Morgan Healthcare Conference (January 2024)Conference18 slidesJan 8, 2024
Q3 2023 Earnings PresentationEarnings53 slidesNov 8, 2023
Q3 2023 Earnings PresentationEarnings54 slidesNov 8, 2023
Merger or Acquisition (October 2023)Merger or acquisition21 slidesOct 4, 2023
Q2 2023 Earnings PresentationEarnings54 slidesAug 2, 2023
Investor Day (May 2023)Investor day77 slidesMay 18, 2023
Q1 2023 Earnings PresentationEarnings42 slidesMay 10, 2023
Q4 2022 Earnings PresentationEarnings46 slidesFeb 8, 2023
41st Annual J.P. Morgan Healthcare Conference (January 2023)Conference17 slidesJan 11, 2023
Fact Sheet (2023)Fact sheet1 slide2023
Q3 2022 Earnings PresentationEarnings39 slidesNov 3, 2022
ESG Presentation (September 2022)Sustainability58 slidesSeptember 2022
Q2 2022 Earnings PresentationEarnings52 slidesJul 27, 2022
Q1 2022 Earnings PresentationEarnings37 slidesMay 3, 2022
FY2021 Earnings PresentationEarnings50 slidesFeb 9, 2022
40th Annual J.P. Morgan Healthcare Conference (January 2022)Conference15 slidesJan 11, 2022
Fact Sheet (2022)Fact sheet1 slide2022
Fact Sheet (2022)Fact sheet1 slide2022
Debt Investor Presentation (2021)Debt investors1 slideDec 5, 2021
Q3 2021 Earnings PresentationEarnings39 slidesOct 27, 2021
Fact Sheet (2021)Fact sheet1 slideSep 18, 2021
Q2 2021 Earnings PresentationEarnings38 slidesJul 28, 2021
Fact Sheet (2021)Fact sheet1 slideMay 16, 2021
Q1 2021 Earnings PresentationEarnings37 slidesApr 28, 2021
J.P. Morgan 2021 Global High Yield & Leveraged Finance ConferenceConference18 slidesMar 2, 2021

This page holds 50 of 167 decks. Open Decks

Open Decks

Financings

RaiseDate
Senior notes
Announced: about US$4.9B
Use of proceeds: Redeem certain existing notes, pay related fees and expenses, and general corporate purposes including repaying outstanding debt
Sep 10, 2026
Senior notes (EUR and USD-denominated)
Made bigger: about US$2.3B
Use of proceeds: Fund tender offers for existing senior notes, pay related fees and expenses, and repay other outstanding debt
May 20, 2025
Debt securities
Announced: debt
Use of proceeds: To fund, with cash on hand, the purchase price of notes bought back in the debt tender offers
May 19, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue17.3B16.5B15.8B14.9B15.9B16.7B16.9B18.3B21.9B21.9B
Cost of revenue8.32B8.48B8.20B7.95B8.28B8.93B9.35B9.97B11.2B10.3B
Gross profit8.94B8.06B7.64B6.97B7.59B7.73B7.54B8.30B10.6B11.7B
Research and development1.01B998.0M953.0M98.0M967.0M997.0M1.01B114.0M175.0M422.0M
Selling, general and administrative1.29B1.16B1.16B1.18B1.10B1.17B1.19B1.30B1.33B1.24B
Operating income2.16B-303.0M433.0M-2.20B1.72B-3.57B-443.0M-1.64B-17.5B2.15B
Depreciation and amortization1.00B1.06B1.15B1.31B1.33B1.56B1.72B1.84B2.11B1.52B
EBITDA3.16B756.0M1.59B-889.0M3.05B-2.02B1.28B205.0M-15.4B3.68B
Interest expense916.0M1.00B1.03B930.0M891.0M901.0M822.0M920.0M875.0M546.0M
Income before tax1.22B-1.28B-624.0M-3.16B658.0M-4.41B-1.26B-2.60B-18.4B824.0M
Income tax-180.0M676.0M-7.00M-643.0M211.0M-168.0M-278.0M-195.0M-1.93B521.0M
Net income1.41B-1.64B-559.0M-2.45B417.0M-3.99B-999.0M-2.15B-16.3B329.0M
Earnings per share, basic1.23-1.45-0.50-2.200.38-3.64-0.91-2.35-16.260.07
Earnings per share, diluted1.21-1.45-0.50-2.200.38-3.64-0.91-2.35-16.260.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.56B3.30B3.23B2.80B2.17B2.18B1.98B1.78B963.0M988.0M
Short-term investments2.00M14.0M679.0M
Receivables3.71B3.06B3.41B3.70B4.53B4.58B5.68B5.82B7.13B7.52B
Inventory3.18B3.01B4.02B3.83B3.82B4.40B4.42B4.73B4.92B4.95B
Current assets13.9B12.6B12.5B12.1B12.6B13.0B13.5B13.8B15.4B17.2B
Property, plant and equipment4.08B4.58B5.75B5.74B5.98B6.30B6.44B6.87B7.67B8.07B
Goodwill16.0B16.0B17.2B17.2B17.6B20.6B24.8B24.9B28.4B44.4B
Total assets40.7B39.3B43.5B44.0B47.7B50.6B57.5B60.7B70.6B93.1B
Accounts payable225.0M158.0M108.0M1.89B1.69B1.76B1.72B1.85B2.07B2.16B
Current liabilities13.5B12.8B12.2B11.5B11.0B13.2B13.7B14.3B17.9B18.5B
Long-term debt15.0B16.0B18.2B19.1B21.6B22.7B24.6B26.7B28.8B32.5B
Total debt1.80B1.76B1.65B2.09B1.40B2.67B1.83B1.70B28.8B32.5B
Total liabilities32.8B33.6B35.4B35.4B36.4B39.6B42.4B44.9B51.9B58.1B
Shareholders' equity7.91B5.37B7.51B7.80B10.3B10.0B14.0B14.7B17.4B33.3B
Shares outstanding1.17B1.17B1.15B1.15B1.13B1.11B1.10B1.10B1.09B1.09B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations1.65B1.25B1.37B1.59B798.0M1.22B748.0M2.45B2.23B3.89B
Capital spending-501.0M-498.0M-526.0M-548.0M-562.0M-578.0M-525.0M-651.0M-874.0M-901.0M
Free cash flow1.15B749.0M842.0M1.04B236.0M638.0M223.0M1.79B1.35B2.99B
Cash from investing737.0M792.0M968.0M656.0M1.52B863.0M1.35B1.87B3.45B-34.4B
Cash from financing-2.15B-1.79B-1.91B-1.49B-2.17B-1.89B-1.93B-3.35B-5.75B25.2B
Dividends paid-52.0M-12.0M-901.0M-1.30B
Share buybacks00
Change in cash256.0M74.0M393.0M636.0M21.0M202.0M193.0M819.0M-25.0M-5.96B

Open Financials

Filings

FilingDateTypeFiled with
144 · Notice of proposed saleNov 20, 2026Other filingsSEC
8-K · Current reportNov 18, 2026Management or board changeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144 · Notice of proposed saleNov 10, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
144 · Notice of proposed saleNov 5, 2026Other filingsSEC
144 · Notice of proposed saleNov 4, 2026Other filingsSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
8-K · Current reportNov 3, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 2, 2026Big-stake noticeSEC
8-K · Current reportOct 29, 2026Management or board changeSEC
3 · Initial statement of ownershipOct 8, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
144 · Notice of proposed saleSep 21, 2026Other filingsSEC
144 · Notice of proposed saleSep 18, 2026Other filingsSEC
8-K · Current reportSep 16, 2026Material contractSEC
8-K · Current reportSep 14, 2026Current reportSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedSep 14, 2026Other filingsSEC
25-NSESep 14, 2026Other filingsSEC
424B5 · ProspectusSep 11, 2026Offer documentSEC
8-K · Current reportSep 11, 2026Current reportSEC
FWP · Free writing prospectusSep 10, 2026Offer documentSEC
FWP · Free writing prospectusSep 10, 2026Offer documentSEC
424B5 · ProspectusSep 8, 2026Offer documentSEC
8-K · Current reportSep 3, 2026Current reportSEC
8-K · Current reportSep 3, 2026Current reportSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
F-6 POSJul 29, 2026Other filingsSEC
10-Q · Quarterly reportJul 29, 2026Quarterly reportSEC
8-K · Current reportJul 29, 2026ResultsSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
144 · Notice of proposed saleJun 11, 2026Other filingsSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
144 · Notice of proposed saleJun 5, 2026Other filingsSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
144 · Notice of proposed saleJun 3, 2026Other filingsSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
8-K · Current reportMay 28, 2026Meeting outcomeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleApr 30, 2026Other filingsSEC
10-Q · Quarterly reportApr 29, 2026Quarterly reportSEC
8-K · Current reportApr 29, 2026ResultsSEC
DEFA14A · Additional proxy materialMar 31, 2026Meeting noticeSEC
ARS · Annual report to shareholdersMar 31, 2026Annual reportSEC
DEF 14A · Proxy statementMar 31, 2026Meeting noticeSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
144 · Notice of proposed saleMar 17, 2026Other filingsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 26, 2026Other filingsSEC
3 · Initial statement of ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
10-K · Annual reportFeb 3, 2026Annual reportSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
8-K · Current reportJan 28, 2026ResultsSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
8-K · Current reportDec 11, 2025Material contractSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
144 · Notice of proposed saleNov 26, 2025Other filingsSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
144 · Notice of proposed saleNov 14, 2025Other filingsSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
144/A · Notice of proposed sale, amendedNov 6, 2025Other filingsSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 6, 2025Big-stake noticeSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
4 · Change in ownershipAug 5, 2025Insider tradeSEC
144 · Notice of proposed saleAug 1, 2025Other filingsSEC
144 · Notice of proposed saleAug 1, 2025Other filingsSEC
10-Q · Quarterly reportJul 30, 2025Quarterly reportSEC
8-K · Current reportJul 30, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 22, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
144 · Notice of proposed saleJun 12, 2025Other filingsSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Teva Pharmaceutical Industries Limited’s releases · as of Sep 10, 2026

Common shares
1,166,292,643
Fully diluted
1,166,292,643

Fully diluted

LineShares
Common shares1,166,292,643

Share count over time

CountShares
Nov 22, 20261,166,292,643

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Clal Insurance Enterprises Holdings Ltd42MUS$1.67BSep 30, 2026
Migdal Insurance & Financial Holdings Ltd.39.4MUS$1.56BSep 30, 2026
Altshuler Shaham Ltd12.4MUS$500MSep 30, 2026
Analyst IMS Investment Management Services Ltd.2.12MUS$83.8MSep 30, 2026
Tri Locum Partners LP1.22MUS$48.5MSep 30, 2026
IFP Advisors, Inc144KUS$5.34MSep 30, 2026
Manufacturers Life Insurance Company, The99,529US$3.94MSep 30, 2026
Rakuten Investment Management, Inc.76,883US$3.06MSep 30, 2026
X-Square Capital, LLC56,230US$2.23MSep 30, 2026
Emerald Advisers, LLC23,162US$917KSep 30, 2026
All 24 holders
HolderSharesValueAs of
Generali Investments CEE, investicni spolecnost, a.s.20,400US$691KSep 30, 2026
Argyle Capital Management, LLC16,200US$642KSep 30, 2026
Cacti Asset Management LLC9,000US$351KSep 30, 2026
Glenmede Trust Co NA8,674US$175KSep 30, 2026
Fort Washington Investment Advisors Inc8,033US$311KSep 30, 2026
Poehling Capital Management, INC.6,499US$257KSep 30, 2026
Winthrop Capital Management, LLC6,000US$238KSep 30, 2026
Vinva Investment Management Ltd1,324US$52,708Sep 30, 2026
E Fund Management (Hong Kong) Co., Ltd.552US$21,859Sep 30, 2026
Asset Planning,Inc400US$15,840Sep 30, 2026
Byrne Asset Management LLC340US$13,365Sep 30, 2026
SHP Wealth Management163US$5,536Sep 30, 2026
Compass Financial Management LLC72US$2,851Sep 30, 2026
Geneos Wealth Management Inc.53US$2,099Sep 30, 2026

Funds

HolderSharesValueAs of
Vanguard Total International Stock Index Fund17.9MUS$608MJul 31, 2026
Vanguard Developed Markets Index Fund11.9MUS$383MJun 30, 2026
New Economy Fund7.71MUS$272MMay 31, 2026
Fidelity International Index Fund4.31MUS$152MMay 31, 2026
New World Fund Inc4.31MUS$151MJul 31, 2026
Fidelity Contrafund3.62MUS$123MJun 30, 2026
Strategic Advisers Fidelity International Fund3.22MUS$114MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio3.12MUS$110MMay 29, 2026
Vanguard Ftse All-World Ex-Us Index Fund2.9MUS$98.4MJul 31, 2026
Old Westbury Large Cap Strategies Fund2.77MUS$96.9MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Schwab International Equity ETF2.66MUS$89.2MMay 31, 2026
Fidelity Series International Value Fund2.39MUS$83.5MJul 31, 2026
Bridge Builder International Equity Fund2.35MUS$79.7MJun 30, 2026
Fidelity Series Global ex U.S. Index Fund2.31MUS$81MJul 31, 2026
Nuveen International Equity Index Fund1.89MUS$66.3MJul 31, 2026
Janus Henderson Global Life Sciences Fund1.88MUS$63.8MJun 30, 2026
First Trust WCM International Equity ETF1.5MUS$50.8MJun 30, 2026
The Hartford International Opportunities Fund1.49MUS$52.2MJul 31, 2026
JNL/WCM Focused International Equity Fund1.38MUS$46.7MJun 30, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF1.36MUS$46MJun 30, 2026
Fidelity International Discovery Fund1.3MUS$45.5MJul 31, 2026
Sound Shore Fund1.27MUS$43MJun 30, 2026
Fidelity Balanced Fund1.18MUS$41.7MMay 31, 2026
Fidelity Value Fund1.11MUS$38.8MJul 31, 2026
Vanguard Total World Stock Index Fund1.03MUS$35MJul 31, 2026
Schwab Fundamental International Equity ETF985KUS$34.8MMay 31, 2026
Lord Abbett Fundamental Equity Fund925KUS$32.4MJul 31, 2026
International Core Equity 2 Portfolio886KUS$30.7MJul 31, 2026
Fidelity Contrafund K6859KUS$29.1MJun 30, 2026
Invesco EQV International Equity Fund850KUS$29.8MJul 31, 2026
JNL Multi-Manager Select Equity Fund839KUS$28.4MJun 30, 2026
Amplify CWP International Enhanced Dividend Income ETF803KUS$27.2MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.795KUS$26.9MJun 30, 2026
VanEck Pharmaceutical ETF794KUS$26.9MJun 30, 2026
Schwab International Index Fund783KUS$27.4MJul 31, 2026
iShares MSCI EAFE International Index Fund742KUS$25.1MJun 30, 2026
William Blair International Leaders Fund732KUS$24.8MJun 30, 2026
VIP Contrafund Portfolio723KUS$24.5MJun 30, 2026
Fidelity Total International Index Fund681KUS$23.9MJul 31, 2026
Variable Portfolio - Partners International Growth Fund665KUS$22.5MJun 30, 2026
Fidelity International Value Fund655KUS$22.9MJul 31, 2026
Fidelity International Equity Central Fund639KUS$21.6MJun 30, 2026
Fidelity Global ex U.S. Index Fund616KUS$21.6MJul 31, 2026
JNL Multi-Manager International Equity Fund601KUS$20.4MJun 30, 2026
Invesco S&P International Developed Momentum ETF579KUS$20.3MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account554KUS$18.8MJun 30, 2026
Impax International Sustainable Economy Fund535KUS$18.1MJun 30, 2026
Strategic Advisers International Fund532KUS$18.8MMay 31, 2026
Fidelity Diversified International Fund511KUS$17.9MJul 31, 2026
Invesco V.I. EQV International Equity Fund500KUS$17MJun 30, 2026

This page holds 50 of 313 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Sabag Mark
Officer: See "Remarks"
Sale44,710USD 44.14US$1.97MNov 12, 2026
Daniell Richard
Officer: EVP, Europe Commercial
Sale20,003USD 42.80US$856KNov 11, 2026
Francis Richard D
Officer: President and CEO
Sale250,000USD 42.24US$10.6MNov 10, 2026
Weiss Amir
Officer: Chief Accounting Officer
Sale662USD 43.15US$28,565Nov 9, 2026
Weiss Amir
Officer: Chief Accounting Officer
Sale7,093USD 43.03US$305KNov 9, 2026
Weiss Amir
Officer: Chief Accounting Officer
Sale9,534USD 43.03US$410KNov 9, 2026
Daniell Richard
Officer: EVP, Europe Commercial
Sale25,000USD 42.91US$1.07MNov 9, 2026
Sabag Mark
Officer: See "Remarks"
Sale46,000USD 41.93US$1.93MNov 5, 2026
Bergwerk Dov
Officer: Interim Cheif Legal Officer
Sale17,505USD 41.72US$730KNov 4, 2026
Bergwerk Dov
Officer: Interim Cheif Legal Officer
Sale8,755USD 41.72US$365KNov 4, 2026
All 32 trades
TradeTradeSharesPriceValueDate
Mignone Roberto
Director
Sale367,600USD 39.06US$14.4MSep 18, 2026
Savage Brian
Officer: Interim Chief Legal Officer
Sale4,503USD 38.69US$174KSep 18, 2026
Savage Brian
Officer: Interim Chief Legal Officer
Sale2,525USD 39.15US$98,854Sep 18, 2026
Savage Brian
Officer: Interim Chief Legal Officer
Sale314USD 38.70US$12,152Sep 18, 2026
Satchi-Fainaro Ronit
Director
Sale415USD 37.25US$15,459Aug 21, 2026
Weiss Amir
Officer: Chief Accounting Officer
Sale6,945USD 37.61US$261KAug 21, 2026
Weiss Amir
Officer: Chief Accounting Officer
Sale2,500USD 37.63US$94,075Aug 21, 2026
Lippman Evan
Officer: EVP, Business Development
Sale18,600USD 36.57US$680KAug 17, 2026
Zaks Tal Zvi
Director
Sale17USD 34.87US$593Aug 5, 2026
Hughes Eric A
Officer: "See ""Remarks"""
Sale25,578USD 34.88US$892KAug 3, 2026
Jover Placid
Officer: "See ""Remarks"""
Sale12,827USD 34.88US$447KAug 3, 2026
Shields Matthew
Officer: EVP, Global Operations
Sale9,989USD 32.19US$322KJun 18, 2026
Kalif Eliyahu Sharon
Officer: EVP, Chief Financial Officer
Sale106,563USD 34.10US$3.63MJun 11, 2026
Francis Richard D
Officer: President and CEO
Sale6,153USD 34.35US$211KJun 5, 2026
Shields Matthew
Officer: EVP, Global Operations
Sale16,195USD 32.87US$532KJun 3, 2026
Kalif Eliyahu Sharon
Officer: EVP, Chief Financial Officer
Sale153,251USD 35.61US$5.46MMay 14, 2026
Lippman Evan
Officer: EVP, Business Development
Sale5,746USD 35.58US$204KMay 14, 2026
Lippman Evan
Officer: EVP, Business Development
Sale35,912USD 35.58US$1.28MMay 14, 2026
Weiss Amir
Officer: Chief Accounting Officer
Sale10,679USD 36.00US$384KMay 6, 2026
Daniell Richard
Officer: EVP, Europe Commercial
Sale30,000USD 35.40US$1.06MMay 5, 2026
Sabag Mark
Officer: "See ""Remarks"""
Sale144,180USD 34.99US$5.04MMay 1, 2026
Fox Christine
Officer: EVP, U.S. Commercial
Sale21,258USD 35.31US$751KApr 30, 2026

Big stakes

StakeStakeSharesDateFiling
Migdal Insurance & Financial Holdings Ltd.5.37%61.7MDec 31, 2025Schedule 13G
Phoenix Financial Ltd.5.00%57.4MJul 14, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Sol J. Barer
Other companies: NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Avalo Therapeutics, Inc. (Director · Feb 3, 2020 – Jun 15, 2021 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); CervoMed Inc. (Director · Nov 1, 2013 – Jul 24, 2014 · Past); Aevi Genomic Medicine LLC (Director · Jun 30, 2012 – Feb 3, 2020 · Past); InspireMD Inc. (Director · Jul 11, 2011 – Dec 7, 2016 · Past); Aegerion Pharmaceuticals Inc (Director · May 1, 2011 – Nov 29, 2016 · Past); Amicus Therapeutics Inc (Director · Jan 6, 2009 – Jun 9, 2016 · Past); Celgene Corporation (Director · Dec 31, 2005 – Jan 13, 2011 · Past)
Director · Since at least Jan 1, 2018
Gabrielle Sulzberger
Other companies: Eli Lilly and Company (Director · Since at least Jan 25, 2021); Mastercard Incorporated (Director · Since at least Dec 1, 2018); Warby Parker Inc. (Director · Sep 21, 2021 – Jun 7, 2024 · Past); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); Brixmor Property Group Inc. (Director · Jun 8, 2015 – Jun 1, 2021 · Past); Stage Stores Inc (Director · Jun 7, 2012 – Jun 10, 2014 · Past); Whole Foods Market Inc (Director · Nov 16, 2011 – Aug 28, 2017 · Past)
Director · Jan 1, 2018 – Jan 1, 2018 · Past
Rosemary A. Crane
Other companies: Certara, Inc. (Director · Since at least Jul 21, 2022); Tarsus Pharmaceuticals, Inc. (Director · Aug 11, 2021 – Jun 24, 2024 · Past); Catalent Inc (Director · Feb 16, 2018 – Oct 27, 2023 · Past); PDS Biotechnology Corporation (Director · Sep 18, 2017 – Mar 15, 2019 · Past); Unilife Corp (Director · Oct 28, 2016 – Oct 28, 2016 · Past)
Independent Director · Since at least Jan 1, 2018
Edward Jordan
Other companies: ALK-abello A/S Class B (Executive Vice President, Commercial Operations North America · Since at least Dec 1, 2025); DBV Technologies SA (EVP and head of Commercial Operations North America · Since at least Dec 1, 2025); Humanigen Inc (Chief Commercial Officer · Aug 24, 2020 – Jul 27, 2022 · Past); AMAG Pharmaceuticals Inc (SVP, Sales and Marketing · Feb 24, 2014 – Mar 3, 2015 · Past)
EVP and head of Commercial Operations North America · Since at least Dec 1, 2025
Janet S. Vergis
Other companies: Dentsply Sirona Inc. (Director and Science and Technology Committee Chair · Since at least Sep 25, 2019); Church & Dwight Company, Inc. (Director since 2014 · Since at least May 1, 2014); Amneal Pharmaceuticals, Inc. (Director · May 4, 2018 – May 6, 2019 · Past); Impax Laboratories Inc (Director · Oct 7, 2015 – May 4, 2018 · Past)
Director · Since at least Jun 9, 2020
David R McAvoy
Other companies: Fresh Tracks Therapeutics Inc. (Gen Counsel, CCO, & Secretary · Jan 24, 2023 – Oct 2, 2023 · Past); Brickell Biotech Inc (General Counsel and CCO · Aug 31, 2019 – May 5, 2022 · Past); Endocyte Inc (General Counsel · Nov 8, 2018 – Dec 21, 2018 · Past)
EVP, Chief Legal Officer · Since at least Mar 4, 2024
Gerald Lieberman
Other companies: Entera Bio Ltd. (Director · Since at least Jan 1, 2022); Forest Laboratories Inc (Director · Aug 23, 2011 – Jul 1, 2014 · Past); AllianceBernstein Holding L.P. (President and COO, Director · Feb 3, 2006 – Jan 23, 2009 · Past)
Independent Director · Since at least Jan 1, 2018
Murray A Goldberg
Other companies: Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – May 18, 2020 · Past); Regeneron Pharmaceuticals, Inc. (SVP Administration & Asst Secr · Jan 9, 2006 – Dec 16, 2014 · Past)
Director · Jan 1, 2018 – Jun 11, 2019 · Past
Brendan O’Grady
Other companies: Nasus Pharma Ltd. (Chief Executive Officer, Director · Since at least Jul 27, 2026); Assertio Holdings, Inc. (CEO, Director · Since at least May 29, 2024)
EVP, North America Commercial · Jan 1, 2018 – Mar 4, 2021 · Past
Dan S Suesskind
Other companies: Nano-X Imaging Ltd (Director · Since at least Mar 18, 2026); Ness Technologies Inc (Director · Jan 4, 2007 – Nov 6, 2007 · Past)
Director · Jan 1, 2018 – Jan 19, 2018 · Past
All 45 people
PersonSeat
Kare Schultz
Other companies: Hims & Hers Health, Inc. (Director · Since at least Jul 16, 2024); International Flavors & Fragrances, Inc. (Director · Feb 1, 2021 – May 4, 2022 · Past)
President and CEO, Director · Jan 1, 2018 – Nov 1, 2022 · Past
Nechemia J. Peres
Other companies: Via Transportation, Inc. (Managing Partner and Co-Founder of Pitango Venture Capital · Since at least Sep 11, 2025); Taboola.com Ltd. (Director · Since at least Jan 1, 2023)
Director · Jun 11, 2019 – Aug 4, 2022 · Past
Roberto A. Mignone
Other companies: Guardant Health, Inc. (Director · Since at least Oct 21, 2024); Avanti Acquisition Corp (Director · Oct 1, 2020 – Oct 1, 2020 · Past)
Independent Director · Since at least Jan 1, 2018
Tal Zaks
Other companies: Moderna, Inc. (Chief Medical Officer · Dec 7, 2018 – Jun 30, 2021 · Past); Adaptimmune Therapeutics PLC (Director · Nov 14, 2016 – Jul 1, 2022 · Past)
Independent Director · Since at least Oct 1, 2021
Amir Elstein
Other companies: Tower Semiconductor Ltd. (Chairman of the Board · Since at least May 29, 2026)
Independent Director · Since at least Jan 1, 2018
Chen Lichtenstein
Other companies: ZIM Integrated Shipping Services Ltd. (President & Chief Executive Officer · Since at least Jun 1, 2026)
Independent Director · Since at least Dec 1, 2024
David Matthew Stark
Other companies: Assertio Holdings, Inc. (Director · Since at least Nov 7, 2024)
Exec. VP Chief Legal Officer · Jan 1, 2018 – Mar 6, 2023 · Past
Eric A. Hughes
Other companies: Monte Rosa Therapeutics, Inc. (Executive Vice President, Global Research & Development Chief Medical Officer, Teva Pharmaceuticals · Since at least Dec 11, 2024)
"See ""Remarks""" · Since at least Aug 1, 2022
Richard Francis
Other companies: Mettler-Toledo International, Inc. (Director · Nov 9, 2023 – Nov 12, 2024 · Past)
President and CEO · Since at least Feb 15, 2024
Varda Shalev
Other companies: Pluri Inc. (Director · Jul 15, 2021 – Jul 15, 2021 · Past)
Director · Since at least Sep 1, 2023
Amir WeissChief Accounting Officer · Since at least Nov 24, 2021
Andrew WeilChief Accounting Officer · Feb 15, 2021 – Nov 2, 2021 · Past
Angus GrantEVP, Business Development · Aug 1, 2023 – Aug 9, 2024 · Past
Brian SavageInterim Chief Legal Officer · Since at least Feb 11, 2026
Carlo de NotaristefaniExecutive VP Global Operations · Jan 1, 2018 – May 18, 2019 · Past
Christine FoxEVP, U.S. Commercial · Since at least Nov 20, 2023
Deborah A GriffinChief Accounting Officer · Jan 1, 2018 – Mar 17, 2020 · Past
Dov BergwerkInterim Chief Legal Officer · Since at least Oct 13, 2023
Dvorah HaneviahUntil Jun 8, 2026 · Past
Eli ShaniEVP,Global Marketing&Portfolio · Aug 15, 2021 – Mar 3, 2023 · Past
Eliyahu Sharon KalifEVP, Chief Financial Officer · Since at least Dec 22, 2019
Eric DrapeExecutive VP Global Operations · Oct 2, 2019 – Mar 5, 2024 · Past
Evan LippmanEVP, Business Development · Since at least Mar 31, 2025
Galia Inbar"See ""Remarks""" · Aug 15, 2021 – Mar 3, 2023 · Past
Gianfranco NazziEVP, International Markets · Jan 1, 2018 – Mar 4, 2021 · Past
Hafrun FridriksdottirExecutive VP, Global R&D · Jan 1, 2018 – May 17, 2022 · Past
Jean Michel HalfonDirector · Jan 1, 2018 – Aug 4, 2022 · Past
Mark SabagSee "Remarks" · Since at least Feb 6, 2018
Matthew ShieldsEVP, Global Operations · Since at least Jun 3, 2024
Perry D. NisenDirector · Since at least Jun 5, 2021
Placid Jover"See ""Remarks""" · Since at least Aug 1, 2024
Richard DaniellEVP, Europe Commercial · Since at least Sep 9, 2019
Ronit Satchi-FainaroIndependent Director · Since at least Jun 11, 2019
Sven DethlefsEVP, North America Commercial · Jan 1, 2018 – Mar 6, 2023 · Past
Vikki L Conway"See ""Remarks""" · Sep 25, 2023 – May 13, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Teva Pharmaceutical Industries Limited.